Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 10Completed 7Active not recruiting 4Not yet recruiting 3Terminated 2

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

obinutuzumab 3fludarabine 3Rituximab 3Cyclophosphamide 3zanubrutinib 2orelabrutinib 2glofitamab 2Bendamustine Hydrochloride 2venetoclax 1tafasitamab 1resiniferatoxin 1polatuzumab vedotin 1pirtobrutinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Interleukin-2 1CT-P10 1Bortezomib 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Mantle-Cell × obinutuzumab × Clear all
NCT06656221 2024-11-19

A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

Ruijin Hospital

Phase 2 Not yet recruiting
29 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT06427213 2024-05-23

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Henan Cancer Hospital

Phase 2 Not yet recruiting
41 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT06324994 2024-03-22

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Dalian Medical University

Phase 2 Not yet recruiting
10 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡